Table 4. Adjusted analysis for the association between troponin levels and 60-days mortality, and between troponin levels and 30-days composite of invasive ventilation support and mortality in patients hospitalized with COVID-19.

Characteristic	Mortality		Composite Outcome of Invasive Ventilation Support and Mortality
	HR a [95% CI]	p-value	HR a [95% CI b]	p-value
Sex = Male	2.00 [0.92, 4.36]	0.081	1.74 [0.98, 3.07]	0.058
Age	1.07 [1.04, 1.11]	<0.001	1.03 [1.01, 1.05]	0.001
Elevated Troponin	4.32 [2.08, 8.99]	<0.001	1.96 [1.15, 3.37]	0.014
Atrial Fibrillation	1.12 [0.52, 2.40]	0.781	1.09 [0.55, 2.13]	0.81
Ischemic Heart Disease	1.42 [0.65, 3.09]	0.383	0.90 [0.44, 1.82]	0.767
Heart Failure	1.03 [0.42, 2.55]	0.947	1.20 [0.55, 2.63]	0.647
Diabetes Mellitus	0.97 [0.45, 2.09]	0.941	1.13 [0.64, 1.98]	0.673
Chronic Kidney Disease	1.67 [0.69, 4.06]	0.258	0.76 [0.36, 1.61]	0.471
Cerebrovascular Accident	1.90 [0.83, 4.32]	0.128	1.33 [0.63, 2.82]	0.452
Hypertension	0.93 [0.42, 2.06]	0.863	0.69 [0.39, 1.25]	0.224
Beta Blockers Therapy	1.13 [0.56, 2.30]	0.731	1.31 [0.71, 2.39]	0.385
ACE c or ARB d Therapy	0.66 [0.23, 1.90]	0.442	0.70 [0.30, 1.64]	0.412
HMG CoA Reductase Inhibitors	1.13 [0.55, 2.29]	0.744	0.97 [0.56, 1.69]	0.918
Low SBP e, f	2.38 [1.09, 5.21]	0.03	4.05 [2.26, 7.27]	<0.001
Creatinine level f	1.02 [0.69, 1.52]	0.91	1.03 [0.77, 1.37]	0.857
Lymphopenia f	0.65 [0.33, 1.29]	0.219	1.13 [0.68, 1.87]	0.631

^a hazard ratio.

^b confidence interval.

^c angiotensin-converting-enzyme inhibitors.

^d angiotensin II receptor blocker.

^e systolic blood pressure.

^f Measured within 24-hours from admission.